Press Releases

LAGUNA BEACH, Calif. and TUCSON, Ariz., March 19, 2020 /PRNewswire/ -- There are over 30 million children nationwide who rely heavily on school meals for their basic nutrition every day.

BEIJING, March 19, 2020 /PRNewswire/ -- With the novel coronavirus sweeping across the planet, infecting an increasing number of people, the world faces severe challenges in preventing and controlling the pandemic.

BOZEMAN, Mont., March 19, 2020 /PRNewswire/ -- Pulsara recently announced they are offering their healthcare communication platform for free for COVID-19 management. While Pulsara

LONDON, March 19, 2020 /PRNewswire/ -- Following the NHS's recent letter&nbs

EATONTOWN, N.J., March 19, 2020 /PRNewswire/ -- Caregility, a clinical collaboration and communications company focused on providing secure, reliable two-way audio and video communications for any devic

CEDAR KNOLLS, N.J., March 19, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, will announce financial results for the fourth quarter of 2019 on

YOKNEAM, Israel, March 19, 2020 /PRNewswire/ -- ChroniSense Medical, developer of Polso™, a wearable, medical-grade, disease management device for multiple clinical applications, announced the appointment of Bridget Ross as Chief Executive Officer (CEO) effective February 10, 2020."We are pleased Bridget will bring her talents to ChroniSense as CE

CORPUS CHRISTI, Texas, March 19, 2020 /PRNewswire/ -- Capital Square 1031, a leading sponsor of Delaware statutory trust (DST) offerings, announced today the launch of CS1031 MOB TX VI, DST, a Regulation D private placement for investors seeking tax deferral under Section 1031 of the Internal Revenue Code and cash investors seeking

VANCOUVER, March 19, 2020 /PRNewswire/ - BirdView Insight Inc. of Vancouver, BC announces today that its BVDash collaboration, communication and project management software will be made available at no cost for a subscription period of six months to support organizations worldwide affected by the current Coronavirus (COVID19) cris

JERUSALEM, March 19, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Company's M-001 universal influenza vaccine candidate.